Our broad-based transaction experience extends across a range of situations, industries and enterprise values
Categories
Year
Type
Industry
Announced: March 13, 2023Value: $44.5 billionStatus: PendingExclusive financial advisor to Seagen on its sale to Pfizer
Announced: July 6, 2023Value: Up to $18.5 billionStatus: PendingFinancial advisor to FIS on its sale of a majority stake in its Worldpay business to GTCR
Announced: February 6, 2023Value: $17 billionStatus: ClosedFinancial advisor to Newmont on its proposal for an acquisition of Newcrest Mining Limited
Announced: April 16, 2023Value: $10.8 billionStatus: PendingFinancial advisor to Prometheus on its sale to Merck
Announced: February 8, 2023Value: $10.6 billionStatus: ClosedSole financial advisor to Oak Street Health on its sale to CVS Health
Announced: April 12, 2023Value: $8.6 billionStatus: PendingFinancial advisor to Emerson on its acquisition of NI
Announced: May 10, 2023Value: $7.1 billionStatus: PendingLead financial advisor to Syneos Health on its sale to a private investment consortium comprised of Elliott Investment Management, Patient Square Capital and Veritas Capital
Announced: April 30, 2023Value: $5.9 billionStatus: PendingFinancial advisor to Iveric on its sale to Astellas
Announced: March 8, 2023Value: $4.6 billionStatus: PendingFinancial advisor to Diversey on its sale to Solenis
Announced: July 25, 2023Value: $3.6 billionStatus: PendingFinancial advisor to Thales on its acquisition of Imperva from Thoma Bravo
Announced: June 12, 2023Value: Up to $3.5 billionStatus: PendingExclusive financial advisor to Chinook on its sale to Novartis
Announced: March 13, 2023Value: $2.9 billionStatus: PendingFinancial advisor to Provention on its sale to Sanofi
Announced: August 7, 2023Value: $2.7 billionStatus: PendingFinancial advisor to Sovos Brands on its sale to Campbell
Announced: April 3, 2023Value: $2.5 billionStatus: ClosedExclusive financial advisor to L'Oréal on its acquisition of Aesop from Natura &Co
Announced: June 20, 2023Value: $2.4 billionStatus: ClosedExclusive financial advisor to DICE on its sale to Eli Lilly
Announced: August 7, 2023Value: $2.3 billionStatus: PendingExclusive financial advisor to Kohlberg & Company on its acquisition of Worldwide Clinical Trials
Announced: July 27, 2023Value: €1.7 billionStatus: PendingExclusive financial advisor to Kering on its acquisition of a significant share of Valentino from Mayhoola
Announced: April 20, 2023Value: $2.1 billionStatus: ClosedExclusive financial advisor to OneOncology and General Atlantic on OneOncology's sale to TPG and AmerisourceBergen
Announced: April 18, 2023Value: $2 billionStatus: PendingExclusive financial advisor to BELLUS on its acquisition by GSK plc
Announced: September 8, 2023Value: $1.9 billionStatus: PendingExclusive financial advisor to C&S on its acquisition of 413 stores, eight distribution centers and two offices that have become available from the Kroger and Albertsons merger
Announced: January 9, 2023Value: Up to $1.8 billionStatus: PendingExclusive financial advisor to CinCor Pharma on its sale to AstraZeneca
Announced: May 10, 2023Value: $1.7 billionStatus: PendingFinancial advisor to CTI on its sale to Sobi
Announced: January 8, 2023Value: Up to $1.5 billionStatus: PendingExclusive financial advisor to Chiesi Farmaceutici on its acquisition of Amryt Pharma Plc
Announced: May 22, 2023Value: $1.2 billionStatus: PendingLead financial advisor to VectivBio on its sale to Ironwood
Announced: September 8, 2023Value: $1.077 billionStatus: ClosedExclusive financial advisor to Trinseo on its secured term loan financing from Angelo Gordon, Oaktree and Apollo
Announced: August 10, 2023Value: Up to $1.075 billionStatus: ClosedExclusive financial advisor to Inversago on its sale to Novo Nordisk
Announced: July 28, 2023Value: Up to $1 billionStatus: PendingExclusive financial advisor to Pfizer on the sale of a portfolio of preclinical gene therapy programs and enabling technologies to AstraZeneca Rare Disease
Announced: May 30, 2023Value: $800 millionStatus: ClosedFinancial advisor to JBT on the sale of its AeroTech business to Oshkosh
Announced: August 7, 2023Value: $650 millionStatus: PendingFinancial advisor to Nautic Partners and its portfolio company ExactCare Pharmacy, on the acquisition of Tabula Rasa
Announced: July 26, 2023Value: Up to $650 millionStatus: PendingExclusive financial advisor to Teleflex on its acquisition of Palette Life Sciences
Announced: January 17, 2023Value: Up to €437.5 millionStatus: ClosedExclusive financial advisor to Diageo on its acquisition of Don Papa Rum
Announced: April 4, 2023Value: $500 millionStatus: ClosedExclusive financial advisor to Thomson Reuters on the sale of a majority ownership stake in its Elite business to TPG, establishing Elite as an independent legal tech company
Announced: July 17, 2023Value: $455 millionStatus: PendingExclusive financial advisor to Johnson Controls on its acquisition of FM:Systems
Announced: March 27, 2023Value: $375 millionStatus: PendingExclusive financial advisor to Li-Cycle on its conditional commitment for a loan from the U.S. Department of Energy
Announced: February 16, 2023Value: $220 millionStatus: PendingExclusive financial advisor to IFF on the sale of its Flavor Specialty Ingredients business to Exponent
Announced: August 9, 2023Value: Up to $213 millionStatus: ClosedExclusive financial advisor to Decibel on its sale to Regeneron Pharmaceuticals
Announced: June 8, 2023Value: $100 millionStatus: PendingExclusive financial advisor to Designer Brands on its Dutch Auction tender offer and new term loan financing
Announced: September 13, 2023Status: ClosedExclusive investment banker to the ad-hoc group of secured creditors on the completion of an out-of-court recapitalization and comprehensive deleveraging transaction for Learfield
Announced: August 8, 2023Status: PendingExclusive financial advisor to the ad-hoc group of secured creditors on National CineMedia's completion of its financial restructuring and emergence from chapter 11
Announced: June 26, 2023Status: PendingFinancial advisor to Kering on its acquisition of Creed
Announced: June 20, 2023Status: PendingFinancial advisor to Santhera on its exclusive license and collaboration agreement for vamorolone in North America with Catalyst Pharmaceuticals
Announced: June 18, 2023Status: PendingFinancial advisor to SVB Financial Group on the sale of SVB Securities to the Management Team Group led by Jeff Leerink and backed by Baupost
Announced: June 5, 2023Status: PendingFinancial advisor to Bansk Group and its portfolio company Arcadia, on Arcadia's acquisition of Avrio Health
Announced: June 1, 2023Status: PendingLead financial advisor to CarepathRx on the announcement of a two-step sale of Carepath Health System Solutions to Cigna
Announced: May 30, 2023Status: ClosedFinancial advisor to Riverbed on its sale to Vector Capital
Announced: May 17, 2023Status: ClosedCo-Manager on Gates’ secondary offering of shares held by Blackstone affiliates
Announced: April 5, 2023Status: ClosedExclusive investment banker to the BrandCo Ad-Hoc Group to Revlon on the Company's Plan of Reorganization
Announced: March 19, 2023Status: PendingSole financial advisor to Credit Suisse on its merger with UBS
Announced: March 10, 2023Status: ClosedFinancial advisor to KHAITE on its investment from Stripes
Announced: February 23, 2023Status: PendingExclusive financial advisor to Redx on its merger with Jounce Therapeutics
Announced: February 7, 2023Status: ClosedExclusive financial advisor to Red Collar on its sale of a treats factory to Nestlé Purina PetCare
Announced: February 3, 2023Status: ClosedExclusive financial advisor to Bacardi on its acquisition of a majority interest in D’USSÉ
Announced: February 2, 2023Exclusive financial advisor to IFF on recent changes to its Board of Directors
Announced: January 24, 2023Status: PendingFinancial advisor to the ad hoc group of priority term loan lenders on Serta Simmons Bedding's chapter 11 filing and Restructuring Support Agreement
Announced: January 9, 2023Status: ClosedExclusive financial advisor to Albireo on its sale to Ipsen